For over 40 years, the frontline treatment for osteosarcoma has remained the same: MAP chemotherapy (methotrexate, doxorubicin, cisplatin). While it raised survival rates from 10–20% to around 60–65%, too many children relapse — often because their cancer never responded to treatment in the first place.

At Oslo University Hospital, a pilot study supported by the Bardo Running Club is seeking solutions. Researchers are analysing data from more than 100 patients already treated with MAP, looking at tumor features, scans, and clinical details to find early “biomarkers” that can predict who is unlikely to benefit from standard therapy.

The goal is to move beyond trial and error. By combining clinical data with molecular and imaging biomarkers, doctors could one day personalize treatment from the start — sparing patients months on ineffective drugs and opening doors to new therapies.

This study doesn’t test new drugs directly but lays the foundation for future trials. Findings will be shared internationally to accelerate progress toward first-line treatments tailored to each child.

For families, it’s a step closer to hope: that the future of osteosarcoma care will be guided by precision, not chance.